Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2015

Open Access 01-12-2015 | Research article

Early detection of breast cancer using total biochemical analysis of peripheral blood components: a preliminary study

Authors: Udi Zelig, Eyal Barlev, Omri Bar, Itai Gross, Felix Flomen, Shaul Mordechai, Joseph Kapelushnik, Ilana Nathan, Hanoch Kashtan, Nir Wasserberg, Osnat Madhala-Givon

Published in: BMC Cancer | Issue 1/2015

Login to get access

Abstract

Background

Most of the blood tests aiming for breast cancer screening rely on quantification of a single or few biomarkers. The aim of this study was to evaluate the feasibility of detecting breast cancer by analyzing the total biochemical composition of plasma as well as peripheral blood mononuclear cells (PBMCs) using infrared spectroscopy.

Methods

Blood was collected from 29 patients with confirmed breast cancer and 30 controls with benign or no breast tumors, undergoing screening for breast cancer. PBMCs and plasma were isolated and dried on a zinc selenide slide and measured under a Fourier transform infrared (FTIR) microscope to obtain their infrared absorption spectra. Differences in the spectra of PBMCs and plasma between the groups were analyzed as well as the specific influence of the relevant pathological characteristics of the cancer patients.

Results

Several bands in the FTIR spectra of both blood components significantly distinguished patients with and without cancer. Employing feature extraction with quadratic discriminant analysis, a sensitivity of ~90 % and a specificity of ~80 % for breast cancer detection was achieved. These results were confirmed by Monte Carlo cross-validation. Further analysis of the cancer group revealed an influence of several clinical parameters, such as the involvement of lymph nodes, on the infrared spectra, with each blood component affected by different parameters.

Conclusion

The present preliminary study suggests that FTIR spectroscopy of PBMCs and plasma is a potentially feasible and efficient tool for the early detection of breast neoplasms. An important application of our study is the distinction between benign lesions (considered as part of the non-cancer group) and malignant tumors thus reducing false positive results at screening. Furthermore, the correlation of specific spectral changes with clinical parameters of cancer patients indicates for possible contribution to diagnosis and prognosis.
Literature
1.
2.
Smith RA, Cokkinides V, Brooks D, Saslow D, Shah M, Brawley OW. Cancer screening in the United States, 2011: A review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin. 2011;61(1):8–30.CrossRefPubMed
3.
Pisano ED, Gatsonis C, Hendrick E, Yaffe M, Baum JK, Acharyya S, et al. Diagnostic performance of digital versus film mammography for breast-cancer screening. N Engl J Med. 2005;353(17):1773–83.CrossRefPubMed
4.
Gotzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane Database Syst Rev. 2011;1, CD001877.PubMed
5.
Miller AB, Wall C, Baines CJ, Sun P, To T, Narod SA. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. BMJ. 2014;348.
6.
Hooley RJ, Andrejeva L, Scoutt LM. Breast cancer screening and problem solving using mammography, ultrasound, and magnetic resonance imaging. Ultrasound Q. 2011;27(1):23–47.CrossRefPubMed
7.
Kuhl CK, Schrading S, Leutner CC, Morakkabati-Spitz N, Wardelmann E, Fimmers R, et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol. 2005;23(33):8469–76.CrossRefPubMed
8.
Lord SJ, Lei W, Craft P, Cawson JN, Morris I, Walleser S, et al. A systematic review of the effectiveness of magnetic resonance imaging (MRI) as an addition to mammography and ultrasound in screening young women at high risk of breast cancer. Eur J Cancer. 2007;43(13):1905–17.CrossRefPubMed
9.
Lee CH, Dershaw DD, Kopans D, Evans P, Monsees B, Monticciolo D, et al. Breast cancer screening with imaging: recommendations from the Society of Breast Imaging and the ACR on the use of mammography, breast MRI, breast ultrasound, and other technologies for the detection of clinically occult breast cancer. J Am Coll Radiol. 2010;7(1):18–27.CrossRefPubMed
10.
Duffy MJ. Serum tumor markers in breast cancer: are they of clinical value? Clin Chem. 2006;52(3):345–51.CrossRefPubMed
11.
Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American Society of Clinical O: American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25(33):5287–312.CrossRefPubMed
12.
Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer. 2005;5(11):845–56.CrossRefPubMed
13.
Farlow EC, Patel K, Basu S, Lee BS, Kim AW, Coon JS, et al. Development of a multiplexed tumor-associated autoantibody-based blood test for the detection of non-small cell lung cancer. Clin Cancer Res. 2010;16(13):3452–62.CrossRefPubMed
14.
Lumachi F, Marino F, Orlando R, Chiara GB, Basso SM. Simultaneous multianalyte immunoassay measurement of five serum tumor markers in the detection of colorectal cancer. Anticancer Res. 2012;32(3):985–8.PubMed
15.
Diem M, Griffiths PR, Chalmers JM. Vibrational spectroscopy for medical diagnosis. 40th ed. Chichester: Wiley; 2008.
16.
Bunaciu AA, Hoang VD, Aboul-Enein HY. Applications of FTIR Spectrophotometry in Cancer Diagnostics. Crit Rev Anal Chem. 2014;45(2):156–65.CrossRef
17.
Simonova D, Karamancheva I. Application of Fourier Transform Infrared Spectroscopy for Tumor Diagnosis. Biotechnol Biotechnol Equip. 2013;27(6):4200–7.CrossRef
18.
Zelig U, Mordechai S, Shubinsky G, Sahu RK, Huleihel M, Leibovitz E, et al. Pre-screening and follow-up of childhood acute leukemia using biochemical infrared analysis of peripheral blood mononuclear cells. Biochim Biophys Acta. 2011;1810(9):827–35.CrossRefPubMed
19.
Ostrovsky E, Zelig U, Gusakova I, Ariad S, Mordechai S, Nisky I, et al. Detection of cancer using advanced computerized analysis of infrared spectra of peripheral blood. IEEE Trans Biomed Eng. 2013;60(2):343–53.CrossRefPubMed
20.
Lasch P. Spectral pre-processing for biomedical vibrational spectroscopy and microspectroscopic imaging. Chemometr Intell Lab Syst. 2012;117:100–14.CrossRef
21.
Bird B, Miljkovic M, Romeo MJ, Smith J, Stone N, George MW, et al. Infrared micro-spectral imaging: distinction of tissue types in axillary lymph node histology. BMC Clin Pathol. 2008;8(1):8.CrossRefPubMedPubMedCentral
22.
Toyran N, Lasch P, Naumann D, Turan B, Severcan F. Early alterations in myocardia and vessels of the diabetic rat heart: an FTIR microspectroscopic study. Biochem J. 2006;397(3):427–36.CrossRefPubMedPubMedCentral
23.
Duda RO, Hart PE, Stork DG. Pattern classification. 2nd ed. New York: Wiley; 2001.
24.
Liu KZ, Xu M, Scott DA. Biomolecular characterisation of leucocytes by infrared spectroscopy. Br J Haematol. 2007;136(5):713–22.CrossRefPubMed
25.
Movasaghi Z, Rehman S, Rehman IU. Fourier Transform Infrared (FTIR) Spectroscopy of Biological Tissues. Appl Spectros Rev. 2008;43:134–79.CrossRef
26.
Townsend CM, Beauchamp RD, Evers BM, Mattox KL. Sabiston textbook of surgery. In: W.B. Saunders Company. 19th ed. 2004. p. 838–40.
27.
Mantsch HH, Chapman D. Infrared spectroscopy of biomolecules. New York: John Wiley; 1996.
28.
Bogomolny E, Argov S, Mordechai S, Huleihel M. Monitoring of viral cancer progression using FTIR microscopy: a comparative study of intact cells and tissues. Biochim Biophys Acta. 2008;1780(9):1038–46.CrossRefPubMed
29.
Sahu R, Mordechai S. Fourier transform infrared spectroscopy in cancer detection. Future Oncol. 2005;1(5):635–47.CrossRefPubMed
30.
Andrus PG. Cancer monitoring by FTIR spectroscopy. Technol Cancer Res Treat. 2006;5(2):157–67.PubMed
31.
Whitehead RH, Thatcher J, Teasdale C, Roberts GP, Hughes LE. T and B lymphocytes in breast cancer stage relationship and abrogation of T-lymphocyte depression by enzyme treatment in vitro. Lancet. 1976;1(7955):330–3.CrossRefPubMed
32.
Shimokawara I, Imamura M, Yamanaka N, Ishii Y, Kikuchi K. Identification of lymphocyte subpopulations in human breast cancer tissue and its significance: an immunoperoxidase study with anti-human T- and B-cell sera. Cancer. 1982;49(7):1456–64.CrossRefPubMed
33.
34.
Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res. 2003;9(2):606–12.PubMed
35.
Leong PP, Mohammad R, Ibrahim N, Ithnin H, Abdullah M, Davis WC, et al. Phenotyping of lymphocytes expressing regulatory and effector markers in infiltrating ductal carcinoma of the breast. Immunol Lett. 2006;102(2):229–36.CrossRefPubMed
36.
Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol. 2002;169(5):2756–61.CrossRefPubMed
37.
Tokuno K, Hazama S, Yoshino S, Yoshida S, Oka M. Increased prevalence of regulatory T-cells in the peripheral blood of patients with gastrointestinal cancer. Anticancer Res. 2009;29(5):1527–32.PubMed
38.
Ju S, Qiu H, Zhou X, Zhu B, Lv X, Huang X, et al. CD13 + CD4 + CD25hi regulatory T cells exhibit higher suppressive function and increase with tumor stage in non-small cell lung cancer patients. Cell Cycle. 2009;8(16):2578–85.CrossRefPubMed
39.
40.
Smyth MJ, Teng MW, Swann J, Kyparissoudis K, Godfrey DI, Hayakawa Y. CD4 + CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J Immunol. 2006;176(3):1582–7.CrossRefPubMed
41.
42.
Jesneck JL, Mukherjee S, Yurkovetsky Z, Clyde M, Marks JR, Lokshin AE, et al. Do serum biomarkers really measure breast cancer? BMC Cancer. 2009;9:164.CrossRefPubMedPubMedCentral
43.
Yu J, Sun J, Wang SE, Li H, Cao S, Cong Y, et al. Upregulated expression of indoleamine 2, 3-dioxygenase in primary breast cancer correlates with increase of infiltrated regulatory T cells in situ and lymph node metastasis. Clin Dev Immunol. 2011;2011:469135.CrossRefPubMedPubMedCentral
44.
Metadata
Title
Early detection of breast cancer using total biochemical analysis of peripheral blood components: a preliminary study
Authors
Udi Zelig
Eyal Barlev
Omri Bar
Itai Gross
Felix Flomen
Shaul Mordechai
Joseph Kapelushnik
Ilana Nathan
Hanoch Kashtan
Nir Wasserberg
Osnat Madhala-Givon
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2015
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-015-1414-7

Other articles of this Issue 1/2015

BMC Cancer 1/2015 Go to the issue

Research article

Overexpression of Nrf2 attenuates Carmustine-induced cytotoxicity in U87MG human glioma cells

Research article

Local control in metastatic neuroblastoma in children over 1 year of age

Research article

Plasma membrane proteomic analysis of human Gastric Cancer tissues: revealing flotillin 1 as a marker for Gastric Cancer

Research article

P38 MAPK expression and activation predicts failure of response to CHOP in patients with Diffuse Large B-Cell Lymphoma

Research article

The regulatory and predictive functions of miR-17 and miR-92 families on cisplatin resistance of non-small cell lung cancer

Research article

Combined comparative genomic hybridization and transcriptomic analyses of ovarian granulosa cell tumors point to novel candidate driver genes
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits